The offer of EUR 46.50 per share is a 40.3% premium to Qiagen’s closing price on the XETRA exchange on July 8, 2026, and 46.9% above its three-month volume-weighted average price up to that date. The bid is made through a holding company controlled by the EQT XI fund, with Abu Dhabi Investment Authority (ADIA) and CPP Investments as co-investors. Qiagen’s Supervisory and Managing Boards have unanimously agreed to recommend that shareholders accept the offer.

The offer requires a minimum acceptance of 50% of the share capital plus one share, approval at an extraordinary general meeting, and merger control and foreign investment clearances. It has no financing condition. Closing is expected in mid-2027, after which Qiagen’s shares would be delisted from the Frankfurt Stock Exchange and NYSE. Qiagen, which has about 5,400 employees, will continue to operate under its own name and brand.

“QIAGEN is an outstanding global leader in the life science tools and diagnostics market. We have closely followed the company for many years and long admired the long-standing reputation and positive impact of its products and services, enabling customers to advance cutting-edge science, improve patient outcomes and gain valuable insights from biological samples. QIAGEN’s management team and employees have built an exceptional company with a portfolio of highly attractive products and respected brands, strong market positions and considerable technical expertise. EQT brings deep sector experience, a global network and operational capabilities, and we are proud to partner with QIAGEN’s highly talented and capable employees to further invest in QIAGEN’s continued product innovation and growth,” says Matteo Thun-Hohenstein, Partner at EQT.

Source: Qiagen press release, 21 October 2026 – read the release